(Q41962159)

English

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

scientific article published on 19 May 2014

Statements

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). (English)
Hideyuki Nakagawa
Mitsuhiro Kamimura
Kazuhiro Sakamoto
Michihiro Yoshimi
Yoshifumi Soejima

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit